CIA
BIIB icon

Concurrent Investment Advisors’s Biogen BIIB Stock Holding History

Concurrent Investment Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
+600
New +$115K ﹤0.01% 2007

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Concurrent Investment Advisors's BIIB Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Biogen (BIIB) stake by 2.3% in Q2 2026, buying an estimated $9.56K and bringing the position to 2,272 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

Concurrent Investment Advisors first reported a position in BIIB in Q4 2023 and has held it in 8 quarters since. The position peaked at $785K in Q2 2024. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Concurrent Investment Advisors held 2,272 shares of Biogen worth $491K as of Q2 2026.
  • Concurrent Investment Advisors bought 50 Biogen shares in Q2 2026, an estimated $9.56K.
  • Biogen made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1413 holding.
  • Concurrent Investment Advisors first reported a position in Biogen in Q4 2023 and has held it in 8 quarters since.
  • Concurrent Investment Advisors's Biogen position peaked at $785K in Q2 2024.
  • 1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.